Form 4: HilleVax Director Nanette Cocero Granted 17,199 Restricted Stock Units

HilleVax, Inc. Director Nanette Cocero was granted 17,199 Restricted Stock Units (RSUs) as part of the company's Non-Employee Director Compensation Program, as disclosed in a recent SEC Form 4 filing.

Summary

• Nanette Cocero, a Director of HilleVax, Inc. (HLVX), was granted 17,199 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The grant occurred on June 23, 2025, with a transaction price of $0.00 per RSU at the time of grant.
• These RSUs were issued under the Registrant's Non-Employee Director Compensation Program.
• The RSUs are set to vest 100% on the first anniversary of the grant date (June 23, 2026) or upon a Change in Control, whichever occurs first.
• Vesting is contingent upon Ms. Cocero's continued service on HilleVax's board of directors through the vesting date.
• Following this transaction, Ms. Cocero beneficially owns 17,199 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The document reports a standard, expected compensation event for a director, which is neutral in terms of overall company sentiment. It reflects routine corporate governance and compensation practices.

Positives

• The RSU grant aligns the director's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• It represents a standard practice for compensating non-employee directors, ensuring competitive remuneration for board service.

Negatives

• The issuance of new RSUs, upon vesting, will result in a minor dilution of existing shareholder equity, although this is a common aspect of equity compensation programs.

Future Outlook

The granted Restricted Stock Units are subject to future vesting, which will occur on the first anniversary of the grant date (June 23, 2026) or earlier upon a Change in Control, provided the director continues in service.

Industry Context

This RSU grant is a routine compensation event for a non-employee director in the biotechnology and pharmaceutical industry. Equity-based compensation is a common practice to attract and retain experienced board members and align their long-term interests with company performance.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to non-employee directors is a standard compensation practice across the biotechnology and broader corporate sectors, comparable to similar programs at companies like Moderna, BioNTech, or Pfizer, which often use equity awards to incentivize and retain board members.
• The vesting schedule, tied to continued service or a change in control, is also a common structure for such awards, reflecting typical corporate governance practices for director compensation.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Nanette Cocero, a director of HilleVax, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Minor potential for future dilution upon RSU vesting, but the grant aligns director incentives with shareholder interests.
• Employees: No direct impact mentioned, as this relates to director compensation.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• The 17,199 RSUs are expected to vest on June 23, 2026, or earlier upon a Change in Control, subject to Nanette Cocero's continued service as a director.

Key Dates

Keywords

HilleVax, HLVX, Restricted Stock Units, RSU, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Corporate Governance